WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017185177) METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/185177    International Application No.:    PCT/CA2017/050507
Publication Date: 02.11.2017 International Filing Date: 25.04.2017
IPC:
A61K 47/65 (2017.01), A61P 35/00 (2006.01)
Applicants: ZYMEWORKS INC. [CA/CA]; 540 - 1385 West 8th Avenue Vancouver, British Columbia V6H 3V9 (CA)
Inventors: NG, Gordon Yiu Kon; (CA)
Agent: SALISBURY, Clare; (CA).
DEARDEN, Anthony; (CA).
FERANCE, Stephen; (CA).
KINGWELL, Brian; (CA).
LEE, Brian; (CA).
RIPLEY, Roch; (CA).
SECHLEY, Konrad; (CA).
TSENG, Pablo; (CA).
WILKE, Mark; (CA).
ZIESCHE, Sonia; (CA)
Priority Data:
62/327,304 25.04.2016 US
Title (EN) METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
(FR) PROCÉDÉS D'UTILISATION DE CONSTRUCTIONS DE LIAISON À L'ANTIGÈNE BISPÉCIFIQUES CIBLANT HER2
Abstract: front page image
(EN)213 ABSTRACT Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.
(FR)La présente invention concerne des procédés d'utilisation de constructions de liaison à l'antigène pour traiter des tumeurs HER2+ chez un patient, comme des tumeurs du sein, du poumon, ou de la tête et du cou. Selon certains aspects de l’invention, le volume tumoral chez le patient ayant reçu au moins sept doses de la construction de liaison à l'antigène est inférieur au volume tumoral d'un patient témoin ayant reçu une quantité équivalente de trastuzumab. Selon certains aspects de l’invention, la survie du patient recevant la construction de liaison à l'antigène est accrue par rapport à celle d'un patient témoin recevant une quantité équivalente d'un anticorps témoin non spécifique ou par rapport à celle d'un patient témoin ne recevant pas de traitement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)